Adrenal Cortex Carcinoma

DMMR occurs in a minority of ACC, often without MSI. Although Lynch syndrome accounts for a subset of cases, dMMR is not predictive of clinical features or ICI response. Nonetheless, MMR testing remains important for identifying individuals at hereditary cancer risk.

Finally, data from the Cancer Genome Atlas showed significantly diminished survival outcomes among ACC patients exhibiting high ACLY or FASN expression. These findings underscore the potential importance of exploring the inhibition of lipid synthesis as a promising avenue for further research in the context of human ACC.

P1, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2026 --> Oct 2027

P1, N=26, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial primary completion date: Jul 2026 --> Jun 2025

This case highlights the diagnostic challenge posed by TTF-1-positive gastric tumors, which may be mistaken for metastatic lesions from lung cancer. As TTF-1 expression is not entirely specific to tissues of lung or thyroid origin, diagnosis should be based on a comprehensive evaluation of morphological and immunohistochemical findings, together with clinical information, including treatment response and disease course.

P=N/A, N=54, Recruiting, The Cleveland Clinic | Trial completion date: Aug 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Aug 2026

P=N/A, N=62, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

P=N/A, N=180, Not yet recruiting, Shanxi Bethune Hospital; Shanxi Bethune Hospital

ANLN may be a prognostic biomarker for patients with ACC and may play a role in tumor biology. Further studies are needed to determine whether ANLN is clinically useful as a prognostic factor in the treatment of ACC and to clarify its involvement in the mechanism of malignant progression of ACC.

Our findings highlight CDK1 as a prognostic marker and a therapeutic target across multiple cancers, with particular relevance in ACC. By integrating pan-cancer transcriptomic analysis with structure-based drug discovery, this study not only emphasizes the clinical significance of CDK1 in ACC but also proposes natural compound-derived inhibitors as promising candidates for future therapeutic development.

This case highlights the complexity of interpreting mosaic variants in the TP53 gene, and we propose a testing algorithm to aid in the delineation of this phenomenon when relaying cancer and reproductive risk information in the context of mosaicism.

P2, N=157, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028